Insecticides India Ltd

- The company has about INR135 crores in Capital Work in Progress (CWIP) related to expansion, especially for the L&T plant at Dahej. - No explicit mention of new fundraising through debt or equity in the provided transcript. - Expansion plans include backward integration and new product launches, expecting turnover growth from these projects. - Delays in plant commissioning (Dahej plant) due to pending government approvals, expected to start operations mid-next quarter. - No direct statements about raising funds through debt or equity in the near future were made during the discussions. - Focus is on growing turnover and margins from internal operations and product launches rather than external fundraising.

- Capex of approximately INR 100-110 crores is ongoing, primarily for the new L&T plant in Dahej. - The Dahej technical plant will start production by mid-next quarter after a 2-3 months delay due to government approvals; expected to contribute INR 300-400 crores turnover next fiscal. - Backward integration forms 50% of the Dahej plant's capacity to enhance production and margins. - An additional INR 20-25 crores capex is planned for the Sotanala new unit, focusing on formulations and technical development, with production starting around April next year. - Sotanala's project timeline is approximately 18 months, with investments spread over the current and next fiscal years. - Strategy includes continuous introduction of new generation molecules, mixtures, and focusing on value-added, high-margin proprietary products backed by patents and IPR.

- Anticipated overall revenue growth up to 10% in B2C segment with volume growth around 20% annually. - For FY 25, volume growth guidance is uncertain but expected to remain strong; 20% volume growth in the current year was achieved. - Focus on value-added "Maharatna" products growing from 59% to potentially over 65%-75% of sales in next 2-5 years. - Expansion from new product launches contributing significantly, with a pipeline of 6-7 new products planned annually. - Backward integration and new plant operations at Dahej expected to add approximately INR 100 crores to revenues this fiscal; full year next fiscal estimated INR 300-400 crores. - Biological segment to grow steadily but not doubling this year. - Exports presently small (~5% of sales), projected to grow modestly by 2-3%. - Market share approximated at 5-5.5%, aiming for gradual increase through product innovation and selective portfolio pruning.

- Company aims to achieve double-digit EBITDA margins in the next 1-2 years, with a vision toward 14-15% eventually, though it will be a gradual process. - Anticipates 10% revenue growth in the B2C segment with 20% volume growth, supported by new product launches and increased market reach. - From new backward integration plant at Dahej, expects INR100 crores growth contribution this fiscal and INR300-400 crores turnover from expansion in next fiscal. - Profitability expected to improve with premiumization of product range and focus on value-added, patented, monopolistic products. - Current EBITDA margins are improving but below desired levels (~10% historically; recent pressure due to price declines and competition). - FY24 PAT grew 62% year-on-year, showing positive momentum. - Margin expansion and volume growth expected from better product mix, new launches, and backward integration benefits over next few years.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Insecticides (India) Limited. However, some relevant insights related to market demand and sales outlook include: - The domestic market is the main focus; export contributes only about 5% to total sales. - Expecting 2-3% growth in international markets next year, with maximum export growth capped at around 7-8%. - There is a visible demand recovery and positive market sentiment ahead, driven by above-normal monsoon expectations. - Sales momentum expected to improve with new product launches and increasing demand from farmers and distributors. - Anticipation of up to 10% growth in B2C segment and 20% volume growth overall. - Demand shortages reported recently, but market preparing for the new season, indicating strengthening order traction. - Manufacturing plant at Dahej is ready to start production soon, which may support future order fulfillment. No specific numeric data on order book values was provided.